Connect with us

Technology

Nuren Group Announces Upcoming IPO on National Stock Exchange of Australia (NSX): Empowering Women Through Innovation

Published

on

SYDNEY and KUALA LUMPUR, Malaysia, June 12, 2024 /PRNewswire/ — Nuren Group, a leading digital platform empowering women in parenting, education, and maternity wellness, is excited to announce the launch of its initial public offering (IPO) on the National Stock Exchange of Australia (NSX).

Set to debut at AUD0.20 per share, this IPO marks a significant milestone in the company’s growth journey, offering investors the opportunity to be part of Nuren Group’s success story. 

IPO Details:

Debut Price: AUD0.20 per shareCompletion Date: Mid-July 2024 (estimated)

Established as a pioneer in digital solutions, Nuren Group offers a diverse portfolio that includes leading platforms such as Motherhood.com.my, Motherhood SuperApp, Kelabmama.com and Ibuencer.com, which combined has a user base of 1.8 million and over 10 million page views monthly, catering to a wide range of customers and vendors.

The capital raised through the IPO will fuel Nuren Group’s commitment to expanding its market presence in the parenting, education, and maternity wellness sectors. It will also enhance the company’s technological infrastructure to deliver a seamless user experience. Additionally, the funding will accelerate growth in key strategic areas through innovation.

Nuren Group operates in high-growth markets, with increasing demand for digital solutions in parenting, media planning, and e-commerce. The listing of Nuren Group on the National Stock Exchange of Australia (NSX) aligns with the accelerating pace of digital transformation, presenting a significant opportunity for Nuren Group to capture a larger market share. Additionally, the debut price of AUD0.20 per share offers investors an attractive entry point, promising substantial growth potential as Nuren Group continues to expand and innovate.

Innovative Growth Potential & Investment Focus

Nuren Group is poised for significant growth, leveraging strategic market expansion, technological advancements, and innovative product development. Supported by a well-established portfolio and leading industry brands with a loyal customer base, Nuren Group stands on a solid foundation for future growth.

Founder and CEO of Nuren Group Limited, Petrina Goh said, “As we embark on this exciting journey with our IPO, we are committed to leveraging our expertise and technology to improve the quality of life for our customers and create lasting value for our shareholders. The market for parenting tech is experiencing unprecedented growth, driven by increasing awareness and demand for convenient, effective and personalised care solutions. The global parenting spending market, encompassing baby care products, childcare services, education technology, and parenting apps, is valued at several hundred billion dollars annually and is expected to continue growing significantly. This presents a tremendous opportunity for us to capitalise on the expanding market and meet the evolving needs of modern families.”

Advancing Towards AI Technology and Innovation

Furthermore, Nuren Group plans to enhance its technological offerings with a unique AI-powered parenting chat feature within the Motherhood SuperApp. This innovative feature will assist users by providing personalised support and advice, utilising advanced machine learning algorithms to offer real-time, relevant assistance.

Nuren Group’s decision to announce this Initial Public Offering (IPO) reflects the company’s commitment to driving expansion, enhancing technological infrastructure, and seizing new growth opportunities in key strategic areas.

For more information on Nuren Group’s IPO, including key dates and how to invest, please visit the company website at https://www.nurengroup.com/ and the Public Offer booklet available at https://apply.automic.com.au/NurenGroupLimited.

About Nuren Group

Established in 2013 by entrepreneur Petrina Goh, Nuren Group is Malaysia’s top parenting platform focused on empowering women in parenting, education, and maternity wellness. Our portfolio includes leading platforms such as Motherhood.com.my, Motherhood SuperApp, Kelabmama.com, Ibuencer.com, and Wedding.com.my. These platforms provide innovative solutions and services across media, e-commerce, parenting, and maternity industries, catering to a diverse range of customers and vendors.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/nuren-group-announces-upcoming-ipo-on-national-stock-exchange-of-australia-nsx-empowering-women-through-innovation-302170438.html

SOURCE Nuren Group

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

GMI Cloud Scales Up With New HQ in Mountain View, CA

Published

on

By

GMI Cloud deepens existing Silicon Valley roots, prioritizing collaboration with leading AI innovators 

MOUNTAIN VIEW, Calif., May 16, 2025 /PRNewswire/ — GMI Cloud, a fast-rising provider of GPU-as-a-Service infrastructure purpose-built for AI, today is proud to announce it has moved its headquarters from San Jose, CA to Mountain View, CA to provide more open space for its growing team and the local growing AI native startup community. From hackathons, meetups, technology industry events and more, the closer proximity to top universities and colleges will help GMI Cloud continue to foster the rapid growth of AI throughout Silicon Valley and on a global level.

The new office comes amid strong momentum for GMI Cloud. Since its funding announcement last year, the company has grown exponentially in customers and partnerships, increasing AI development all over the world. However, GMI Cloud has been a global company since day one, with data centers in Taiwan, Malaysia, Mexico, and the U.S. Its global data center network makes it uniquely able to provide flexible, cost-effective computing solutions without the disruption of geopolitical changes. Customers can scale their AI capabilities without unexpected cost surprises. This new office signifies its commitment to AI innovators in Silicon Valley and beyond.

“Bringing GMI Cloud to Mountain View allows for employees to enjoy what the local community has to offer while keeping us in the epicenter of Silicon Valley,” said Alex Yeh, CEO of GMI Cloud. “We are accelerating quickly and we find it incredibly valuable to have the right home base to host our partners, customers, and employees.”

For more information about GMI Cloud and hiring opportunities, visit www.gmicloud.ai.

About GMI Cloud
GMI Cloud is a global company that delivers full-stack, U.S.-based GPU infrastructure and enterprise-grade inference services built to scale AI products. Whether training foundation models or deploying real-time agents, GMI gives teams full control of performance, costs, and launch velocity. With on-demand and reserved GPU clusters for all workloads and projects, GMI helps AI teams build without limits. GMI Cloud is based in Mountain View, CA.

View original content to download multimedia:https://www.prnewswire.com/news-releases/gmi-cloud-scales-up-with-new-hq-in-mountain-view-ca-302458273.html

SOURCE GMI Cloud

Continue Reading

Technology

STL reports FY25 results; well-positioned to unlock growth

Published

on

By

Reports EBITDA of INR 146 Cr, highest in the last six quarters; 31% QoQ growth

MUMBAI, India, May 17, 2025 /PRNewswire/ — STL (NSE: STLTECH), a leading optical and digital solutions company, today announced its financial results for the year ended 31 March, 2025. The Company reported revenues of INR 1052 Cr for the quarter and INR 3996 Cr for FY25 across its business units – Optical Networking and Digital. STL delivered EBITDA margins of 13.8% and EBITDA of INR 146 Cr, highest in the last six quarters.

With a focus on customer centricity, product innovation, and cost leadership, STL continues to be a partner of choice for the global Digital Infrastructure build. As we navigate evolving tariff dynamics, we remain focused on leveraging our global manufacturing footprint in the U.S., Europe, and India and diversified supplier partnerships to drive company performance. 

In Q4 FY25, Optical Networking Business reported a 26% revenue growth and 110% EBITDA as compared to Q4 FY24. This was driven by accelerating momentum in the Enterprise Connectivity and Data Centre Business and a ~22% attach rate in the Optical Connectivity Business (OC). Enterprise and Data Centre Business has seen robust demand in Europe and India as STL supported key players in these regions to expand their end customer connectivity solutions.

STL Digital – Achieved EBITDA positive for consecutive 2 quarters with a steady YoY revenue growth and a robust order book. STL Digital has strategic partnerships with 40+ technology companies and has acquired more than 25 global customers across India and the U.S.

Some key highlights for FY25

Global Services Business* – STL completed the demerger of its Global Services Business that transitioned from Sterlite Technologies (STL) to STL Networks Limited under the brand name ‘Invenia.’Our marquee wins – STL added diversified customers across geographies, forming deep partnerships with service providers like Archtop Fiber in the U.S., Connexin, Netomnia and Wyre in the UK and Europe, Vocus in Australia, du Telecom in MEA and Bharatnet and Vedanta in India.Product innovation and co-creation with customers – STL has aggressively driven product innovation, focusing on co-creation with customers and next-gen optical solutions with development of ultra-thin optical fibre of 160-micron, 180-micron and 864F Microcables, AI-led data centre solutions, Multi-core fibre (MCF) for quantum communications and silicon photonics, and Optical Connectivity portfolio for the U.S. STL also unveiled Rapid series of Optical products, compliant with the ‘Build America, Buy America’ (BABA) regulations. STL ended the year with a patent count of 740 with 76 new patents filed in FY25.Our Net Debt: Equity has improved to 0.68 times against 1.39 times post demerger and Post QIP (YoY).

“FY25 was marked by resilience and customer-focus. By doubling down on our core priorities—Customer and Cost Leadership—we not only sustained momentum but also laid the groundwork for future growth. The strengthening order pipeline and customer engagements signal a promising shift in market dynamics,” remarked Ankit Agarwal, Managing Director, STL. “The trifecta of AI-ready infrastructure, rural fiberisation, and data centre expansion will be the cornerstone of global digitalisation, and we’re are fully prepared with our extensive Connectivity solutions,” he added.

Financial highlights (INR Cr)

Financials**

INR Cr

FY25

FY24

Q4FY25

Q4FY24

Revenue

3996

4083

1052

843

EBITDA

452

527

146

44

**All financials are from continued operations

*Pursuant to receipt of necessary statutory approvals and in accordance with the Scheme of Arrangement between STL and STL Networks Limited, the Company has demerged its Global Service business effective March 31, 2025, as approved by NCLT. Consequently, the financial results of the Global Service business for the respective quarters and year ended March 31, 2025 and March 31, 2024 have been presented as discontinued operations to reflect the impact of this demerger.

About STL – Sterlite Technologies Ltd:

STL is a leading global optical and digital solutions company providing advanced offerings to build 5G, Rural, FTTx, Enterprise and Data Centre networks. Read more, Contact usstl.tech | Twitter | LinkedInYouTube

For more information, contact:
Media Relations:
Shaily Rai Sinha
stl.communications@stl.tech

Investor Relations
Ajay Jhanjhari 
investor@stl.tech

Logo: https://mma.prnewswire.com/media/2259921/4968402/STL_Logo.jpg

 

View original content:https://www.prnewswire.com/in/news-releases/stl-reports-fy25-results-well-positioned-to-unlock-growth-302457858.html

Continue Reading

Technology

Innovations in High Blood Pressure Intervention Benefit Patients with Resistant Hypertension

Published

on

By

World Hypertension Day’s focus on High Blood Pressure Awareness, Management and Control highlights Importance of New Therapies, like Ultrasound Renal Denervation from Recor Medical

PALO ALTO, Calif., FRANKFURT, Germany, May 17, 2025 /PRNewswire/ — May 17, 2025, is World Hypertension Day, a day dedicated to raising awareness about high blood pressure, also known as the “silent killer” because many people do not know they have it and, over time, it can lead to serious health issues. The theme of World Hypertension Day, “Measure Your Blood Pressure Accurately, Control It, Live Longer!” highlights the importance of not only awareness but also accurate monitoring, diagnosis, and treatment of hypertension.

According to a report from the World Health Organization, the number of adults with hypertension doubled between 1990 and 2019 from 650 million to 1.3 billion. The report also states that only 54 percent of adults with hypertension are diagnosed and only 42 percent receive treatment. And recent studies1,2 have suggested that BP assessment in the clinical setting can often get a hypertension diagnosis wrong or miss it completely. Left undetected or uncontrolled, hypertension is a leading contributor to serious health risks, including heart attack, stroke and kidney disease, making accurate diagnosis, monitoring and treatment of the condition critical.

About one-third of the patients who are treated for hypertension remain uncontrolled despite making healthy lifestyle changes and taking more than three medications. For these patients, innovation and investment in new solutions are vital to achieve blood pressure control and realize a healthier future. From pharmaceutical treatments to technology, patients need new therapies that can provide life-changing results. This includes medical device-based therapies, like the Paradise™ Ultrasound Renal Denervation (uRDN) system, an additional treatment option for patients who remain uncontrolled and at elevated cardiovascular risk despite standard lifestyle changes and treatment with oral medications.

The Paradise uRDN system is a first-of-its-kind ultrasound-based RDN technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension. The Paradise uRDN system delivers two to three doses of 360-degree ultrasound energy — lasting seven seconds each — through the main renal arteries to the surrounding nerves.* The Paradise catheter features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to help protect the renal artery wall. This minimally invasive procedure is supported by many medical societies including the American Heart Association, the American College of Cardiology, the European Society of Cardiology and others.

“Taking a risk-based approach to hypertension makes sense and this is why the medical societies are increasingly behind it,” said Prof. Andrew Sharp, University College Dublin and The Mater Misericordiae Hospital, Dublin, Ireland. “Blood pressure reductions of just 5 to 10mmHg can have a significant impact on the risk of cardiovascular complications, such as stroke and heart attack, but gain is greatest in those who are most at risk, such as patients who also have other risk factors for cardiovascular health such as diabetes. Early blood pressure control may also limit the vascular aging process and yet over half of patients worldwide are not even at the basic standard of control of 140/90mmHg. With guidelines now suggesting lower BP targets of 130/80 for many, new treatments in this space are welcome. Renal denervation is a recently approved tool to safely aid in blood pressure lowering throughout the 24-hour cycle and is independent of patient adherence to medication. The procedure shows an excellent safety profile and typically takes under an hour to perform, with lasting BP reductions demonstrated.”

Recor Medical – the manufacturer of the Paradise System – has been focused on developing and testing uRDN for the treatment of hypertension since 2009, and completed three independently powered, sham-controlled, randomized clinical trials, all which demonstrate the efficacy and safety of the Paradise System. Recor has also initiated the US Global Paradise System (GPS) Post-Approval Study to collect real-world clinical evidence with long-term follow-up in 1,000 patients with uncontrolled hypertension in the United States.

The Paradise uRDN system is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. A physician will make a medical assessment to determine if a patient is a candidate for ultrasound renal denervation. The most common risks include pain, vascular access site complications and vasospasm. Full important risk information can be viewed here.

*Anatomies vary. See Paradise IFU for treatment strategies.

Liu H et al.: Arm Position and Blood Pressure Readings. The ARMS Crossover Randomized Clinical Trial. JAMA Intern Med. 2024;184(12):1436-1442. doi:10.1001/jamainternmed.2024.5213https://newsroom.heart.org/news/high-blood-pressure-while-lying-down-linked-to-higher-risk-of-heart-health-complications

About Recor Medical, Inc.
Recor Medical, headquartered in Palo Alto, Calif., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., is a medical technology company focused on transforming the management of hypertension. Recor has pioneered the use of the Paradise Ultrasound Renal Denervation system for the treatment of hypertension. The Paradise uRDN system is an investigational device in Japan, is FDA approved in the United States, and bears the CE mark. Recor has reported positive outcomes in three independent, randomized, sham-controlled studies of the Paradise uRDN system in patients with mild-to-moderate and resistant hypertension. In addition, Recor is conducting the Global Paradise System (“GPS”) Registry in the European Union and the UK, and has initiated the US GPS post-approval study in the United States.
http://www.recormedical.com/

About Otsuka Medical Devices Co., Ltd.
Otsuka Medical Devices Co., Ltd. engages in the global development and commercialization of medical devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment. Otsuka Medical Devices is a subsidiary of Otsuka Holdings Co., Ltd. (www.otsuka.com/en), a global healthcare company listed on the Tokyo Stock Exchange (JP 4578).

https://www.omd.otsuka.com/en/ 

Photo: https://mma.prnewswire.com/media/2689174/RecorMedical_BP_Measure.jpg
Logo:  https://mma.prnewswire.com/media/2689173/Recor_Medical_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/innovations-in-high-blood-pressure-intervention-benefit-patients-with-resistant-hypertension-302458002.html

Continue Reading

Trending